Posted by Michael Wonder on 02 Sep 2022
Azurity Pharmaceuticals announces FDA approval of Konvomep (omeprazole and sodium bicarbonate for oral suspension)
2 September 2022 - Azurity Pharmaceuticals announced today that the US FDA has approved Konvomep (omeprazole and sodium bicarbonate for oral suspension).
Konvomep is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastro-intestinal bleeding in critically ill patients.
